marketplace: the emergence of Immunotherapy to treat cancer and the transition to Precision Medicines that target the right patients with the right drugs at the right doses as the right times. Vicus lead drug, VT-122, is the 1st multi-pathway neuro-immune modulator for the treatment of cancer. VT-122 is a chrono-formulation of etodolac and propranolol that modulate beta adrenergic receptors 1-2, COX-2 enzyme &TRPA1 channel, and the MAPK, PI3K, PKA, AKT and nociception signaling cascades. VT-122 unique MOA, safety and efficacy profile is supported by over one hundred published animal and human studies of its components and component classes across tumor types. VT-122 recently recently completed a Phase 2 study of advanced liver cancer patients receiving sorafenib and investigator-initiated studies of liver, pancreatic and brain cancers. These studies show VT-122 increased median overall survival 4 to 7 months versus standard of care alone and reduced toxicities with no treatment related SAEs. VT-122 has been granted US FDA Orphan Drug designations for the treatment of pancreatic, liver and brain cancers.